HannahBlake, Author at

A history of AstraZeneca

A look back at AstraZeneca and its roots in the UK and Sweden

A history of AstraZeneca

https://pharmaphorum.com/views-analysis-sales-marketing/a_history_of-_astrazeneca/

Sanofi’s Aubagio recommended for use on UK’s NHS

The UK’s National Institute for Clinical and Health Excellence has issued final draft guidance recommending the NHS to

Sanofi’s Aubagio recommended for use on UK’s NHS

https://pharmaphorum.com/news/sanofis-aubagio-recommended-for-use-on-uks-nhs/

Phase 3 goal met by Novartis’ multiple myeloma drug

Novartis’ investigational compound, LBH589, for multiple myeloma has met its primary endpoint in phase 3 clinical trials. LBH589

Phase 3 goal met by Novartis’ multiple myeloma drug

https://pharmaphorum.com/news/phase-3-goal-met-by-novartis-multiple-myeloma-drug/

Lilly’s depression drug fails to meet goal in phase 3

Eli Lilly and Company’s edivoxetine did not meet its primary endpoint in phase 3 clinical trials as an

Lilly’s depression drug fails to meet goal in phase 3

https://pharmaphorum.com/news/lilly-s-depression-drug-fails-to-meet-goal-in-phase-3/

Digital health perspectives: Matt McNally

Matt McNally, President of Publicis Health Media offers his insight into digital engagement in our latest ‘Digital health

Digital health perspectives: Matt McNally

https://pharmaphorum.com/views-and-analysis/digital-health-perspectives-matt-mcnally/

Roche, Molecular Partners in cancer deal worth over $1 billion

Roche and Molecular Partners have entered into a research and licensing alliance to discover, develop and commercialize new

Roche, Molecular Partners in cancer deal worth over $1 billion

https://pharmaphorum.com/news/roche-molecular-partners-in-cancer-deal-worth-over-1-billion/

Sanofi reports positive phase 3 insulin data

Full results from Sanofi’s phase three clinical trials of its investigational new insulin U300 have been announced. The

Sanofi reports positive phase 3 insulin data

https://pharmaphorum.com/news/sanofi-reports-positive-phase-3-insulin-data/

Defects and the development risk defence – an Australian perspective

Mabel Tsui provides us with an Australian perspective on the development risk defence against a pharmaceutical product liability

Defects and the development risk defence – an Australian perspective

https://pharmaphorum.com/views-and-analysis/defects-and-the-development-risk-defence-an-australian-perspective/

Celgene, OncoMed sign $155m cancer deal

OncoMed Pharmaceuticals and Celgene Corporation have signed an agreement to jointly develop and commercialize up to six anti-cancer

Celgene, OncoMed sign $155m cancer deal

https://pharmaphorum.com/news/celgene-oncomed-sign-155m-cancer-deal/

Trending

About HannahBlake

Posts by HannahBlake :

A history of AstraZeneca

Sanofi’s Aubagio recommended for use on UK’s NHS

Phase 3 goal met by Novartis’ multiple myeloma drug

Lilly’s depression drug fails to meet goal in phase 3

Digital health perspectives: Matt McNally

Roche, Molecular Partners in cancer deal worth over $1 billion

Sanofi reports positive phase 3 insulin data

Defects and the development risk defence – an Australian perspective

Celgene, OncoMed sign $155m cancer deal

Search

Advanced Search

Trending

About HannahBlake

Posts by HannahBlake :